The F-1 is a routine shelf registration for existing shareholders to resell, not a primary offering, but the sheer volume of registered shares (120M vs 141M outstanding) creates a massive overhang. With the stock at $1.96, the $11.50 warrants are deeply out-of-the-money and unlikely to be exercised. Monitor for any insider selling or large block trades post-effectiveness. The company's cash runway is very short (CHF 1.6M at YE2025) despite the HTC note and Lincoln Park facility, so a dilutive equity raise is likely within 12 months.
Executive Summary
Veraxa Biotech AG filed an F-1 registration statement to register the resale of up to 120,295,385 ordinary shares and 6,786,739 private warrants by selling securityholders, and the issuance of up to 19,436,739 ordinary shares upon exercise of public and private warrants. The company is a post-SPAC oncology biotech with no approved products, deep losses (CHF 66.6M accumulated deficit), and a market cap of $277M at a $1.96 stock price. This is a routine shelf registration for existing securities, not a new capital raise, but the massive overhang of registered shares (86% of outstanding) creates significant near-term dilution risk given the stock trades far below the $11.50 warrant exercise price.
Key Facts
- F-1 registers up to 120,295,385 ordinary shares for resale by selling securityholders, representing ~85% of the 141.4M shares outstanding.
- Also registers up to 19,436,739 shares issuable upon exercise of warrants at $11.50/share, far above the current $1.96 closing price.
- Company has no approved products, no product revenue, and an accumulated deficit of CHF 66.6M as of Dec 31, 2025.
- Net loss of CHF 66.6M in FY2025, up 137% from CHF 28.1M in FY2024, driven by stock-based compensation.
- Cash balance of only CHF 1.6M as of Dec 31, 2025, with a working capital deficit of CHF 3.7M.
- Post-BC, company secured a $27.5M senior secured note (HTC Financing) and a $50M Lincoln Park equity facility, but the note is secured by all assets.
Financial Impact
Massive potential dilution from up to 120M registered shares (86% of current float) and 19.4M warrant shares; no new cash to company from secondary sales.
Risk Factors
- Massive dilution from registered share resale and future equity raises.
- Cash burn rate unsustainable; CHF 1.6M cash at YE2025 vs CHF 9.9M operating cash burn.
- No approved products or revenue; clinical pipeline is early-stage.
- Stock trades at $1.96, far below $11.50 warrant exercise price, making warrants nearly worthless.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1 Filing (Primary) | 0001829126-26-008247 |
| Document: veraxabiotech_ex107.htm | 0001829126-26-008247 |
| Document: veraxabiotech_ex23-1.htm | 0001829126-26-008247 |
| Document: veraxabiotech_ex23-3.htm | 0001829126-26-008247 |
| Document: veraxabiotech_ex23-2.htm | 0001829126-26-008247 |
| Document: 0001829126-26-008247-index-headers.html | 0001829126-26-008247 |
| Document: 0001829126-26-008247-index.html | 0001829126-26-008247 |
| Document: 0001829126-26-008247.txt | 0001829126-26-008247 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $1.11 | awaiting T+20 | — | $1.00 (−9.91%) |
Sep 4, 2026 7w ago | 6-K | $1.76 $1.13 | ▼ −35.80% | ▼ −36.40% | $1.00 (−43.18%) |
Sep 4, 2026 7w ago | Press Release | $1.76 $1.13 | ▼ −35.80% | ▼ −36.40% | $1.00 (−43.18%) |
Aug 24, 2026 9w ago | 6-K | $1.78 $1.46 | ▼ −17.98% | ▼ −17.99% | $1.00 (−43.82%) |
Aug 10, 2026 11w ago | EFFECT | $1.85 $1.60 | ▲ +13.51% | ▲ +12.60% | $1.00 (+45.95%) |
Aug 7, 2026 11w ago | EFFECT | $1.99 $1.76 | ▲ +11.56% | ▲ +11.16% | $1.00 (+49.75%) |
Jul 31, 2026 12w ago | F-1 | $1.83 $1.35 | ▲ +26.23% | ▲ +27.47% | $1.00 (+45.36%) |
Jul 31, 2026 12w ago | F-1 | $1.83 $1.35 | ▲ +26.23% | ▲ +27.47% | $1.00 (+45.36%) |
Jul 27, 2026 13w ago | 6-K | $1.98 $1.73 | ▼ −12.63% | ▼ −16.01% | $1.00 (−49.49%) |
Jul 27, 2026 13w ago | 6-K | $2.01 $1.78 | ▼ −11.44% | ▼ −14.74% | $1.00 (−50.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers